期刊文献+

肿瘤DNA异常甲基化与组蛋白修饰

Aberrant DNA Methylation and Histone Modification in Tumor
原文传递
导出
摘要 基因启动子区域异常甲基化是肿瘤抑制基因失活的一个关键机制 ,与肿瘤每一步形成有关的基因也能靠这种机制失活。DNA甲基化抑制剂如 5氮杂脱氧胞苷 (5AZA)能逆转这种表观遗传学事件 ,说明可以用它治疗肿瘤。染色质的结构对基因表达调控也起重要作用 ,组蛋白中包含低乙酰化赖氨酸的染色质有一个紧密的结构 ,对转录起抑制作用。组蛋白去乙酰化酶 (HDAC)抑制剂能够使染色质结构开放 ,激活抑制肿瘤生长的某些基因 ,这些组蛋白去乙酰化抑制剂也可用于肿瘤治疗。DNA甲基化与组蛋白去乙酰化的联合作用可以用于沉寂基因转录 ,具体分子机理牵涉到甲基化CpG岛结合蛋白吸附到甲基化启动子上 ,以及吸附组蛋白去乙酰化酶形成抑制转录的复合物 ,这两种表观遗传学修饰代表了用 5AZA和HDAC抑制剂治疗干预的靶位点 ,这两种试剂联合使用显示有重新激活肿瘤抑制基因和增强抗肿瘤细胞增殖的协同效果 ,应当作为表观遗传学治疗肿瘤的新方法加以研究。 Hypermethylation of promoter is the key mechanism of tumor suppressor gene inactivation. The inhibitor of DNA methylation such as 5-azadeoxycytidine(5AZA) can reverse this epigenetic event, suggesting that it can be used for tumor treatment. The chromosome structure also plays a very important role in gene regulation, the chromatin containing hypoacetylated lysine in histone has a compact structure, which can inhibit transcription. The inhibitory agent of histone deacetylase (HDAC) can open chromosome structure, and it can also be used for treating tumors. Combined use of 5AZA and HDAC has better effect in the reactivation of tumor suppressor gene, which should be explored as a new tumor therapy.
作者 余升红
出处 《医学分子生物学杂志》 CAS CSCD 2004年第5期288-291,共4页 Journal of Medical Molecular Biology
  • 相关文献

参考文献19

  • 1Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res, 2002, 62 (22): 6456-61.
  • 2Graff JR, Gabrielson E, Fuji H, et al. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem, 2000,275 (4): 2 727-32.
  • 3Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene, 2002, 21 (35): 5 450-61.
  • 4Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-typespecific patterns. Nat Genet, 2000, 24 (2): 132-8.
  • 5Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet,1999,21 (1): 103-7.
  • 6Gagnon J, Shaker S, Primeau M, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet, 1999, 21(1): 103-7.
  • 7Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Gene,2002, 31 (2): 141-9.
  • 8Herman JG, Graff JR, Myohanen S, et al. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 1996, 93 (18):9 821-6.
  • 9Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res,2003, 63 (5): 1 114-21.
  • 10Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res, 1999, 59 (1): 67-70.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部